September 2013 Issue Table Of Contents

From The Editor

• Private Or Public? Not Really Even A Question In Life Sciences?

Ask The Board

• Ask The Board September 2013

Capitol Perspectives

• Republicans: Stop Allowing Vocal Ideologues To Dictate Health Policy

Companies To Watch

• Esperion Therapeutics, Does Their Cholesterol-Reduction Drug Have “Blockbuster Potential”?

Outsourcing Insights

• The Top CROs By Therapeutic Indication Share Strong Regulatory And Productivity Performance

Bio Innovation notes

• Innovation In Expression Systems Yields Increase Productivity

Feature

• Adaptive Funding: Survival Of The Fittest In The Life Sciences Start-Up Evolution
• AstraZeneca Translates 'Winning With Science' From Words To Action

Inside The Industry

• Establishing A Culture Of Brand Protection In Life Sciences Organizations
• Pfizer’s Hybrid Approach To Implementing Continuous Manufacturing Processes
• The Importance Of Investment And R&D In The Health Of Life Sciences
• Taking Biotech Public: To IPO Or Not To IPO
• How Cloud-Based Tools Can Help With FDA Compliance
• Stealing Competitive Secrets From Pharma Companies
• Looking Into Biopharma IP Protection In China

Industry Leader

• Mitigate Risk With Package Quality
• Should Your Clinical Outsourcing Model Be Functional, Full-Service, Or A Hybrid FSP?
• Cultivate The "I Trust You" Style Of Management